Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Shire Wins European Backing for Vyvanse Attention Deficit Drug

Dec. 18 (Bloomberg) -- Shire Plc won backing to sell its attention deficit drug Vyvanse in eight European countries, paving the way for the company’s top-selling treatment in the U.S. to be marketed in Europe.

The U.K., Denmark, Finland, Germany, Ireland, Norway, Spain and Sweden have recommended approval for Vyvanse as a treatment for children aged six years and over with attention deficit hyperactivity disorder, who don’t respond adequately to Novartis AG’s Ritalin, Dublin-based Shire said in a statement today. The drug will be sold as Tyvense in Ireland and as Elvanse in the other countries.

The eight nations are expected to formally approve the drug within one month to three months, and negotiations with pricing and reimbursement authorities will be required in some countries, Shire, which has management offices in Basingstoke, England, said in the statement. Vyvanse earned Shire $805 million last year, or 19 percent of sales. It may reap $2.2 billion by 2017, according to the average of five analyst estimates compiled by Bloomberg.

“We will now work closely with the pricing and reimbursement authorities in the respective countries to ensure that Elvanse is made available to patients as soon as possible,” Angus Russell, Shire’s chief executive officer, said in the statement.

Shire rose 0.1 percent to 1,925 pence as of 3:01 p.m. in London, giving the company a market value of 10.8 billion pounds ($17.5 billion). The stock has declined 14 percent this year, including reinvested dividends, compared with a 17 percent advance in the Bloomberg Europe Pharmaceutical Index.

To contact the reporter on this story: Simeon Bennett in Geneva at

To contact the editor responsible for this story: Phil Serafino at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.